{"organizations": [], "uuid": "056405168544e27f119d74145c053d8c5cff7c70", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abbvie-announces-positive-topline/brief-abbvie-announces-positive-topline-results-from-phase-3-study-evaluating-investigational-elagolix-in-women-with-uterine-fibroids-idUSFWN1QB0IM", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbvie Announces Positive Topline Results From Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T15:18:00.000+02:00", "replies_count": 0, "uuid": "056405168544e27f119d74145c053d8c5cff7c70"}, "author": "", "url": "https://www.reuters.com/article/brief-abbvie-announces-positive-topline/brief-abbvie-announces-positive-topline-results-from-phase-3-study-evaluating-investigational-elagolix-in-women-with-uterine-fibroids-idUSFWN1QB0IM", "ord_in_thread": 0, "title": "BRIEF-Abbvie Announces Positive Topline Results From Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters) - abbvie inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 21, 2018 / 1:20 PM / Updated 3 minutes ago BRIEF-Abbvie Announces Positive Topline Results From Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids Reuters Staff 1 Min Read Feb 21 (Reuters) - Abbvie Inc: * ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS * PHASE 3 ELARIS UF-I STUDY (M12-815) OF ELAGOLIX MET ITS PRIMARY ENDPOINT * RESULTS DEMONSTRATED ELAGOLIX, IN COMBINATION WITH LOW-DOSE ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING COMPARED TO PLACEBO * PHASE 3 ELARIS UF-I STUDY ALSO MET ALL RANKED SECONDARY ENDPOINTS (P<0.001) AT MONTH SIX Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-21T15:18:00.000+02:00", "crawled": "2018-02-21T15:29:32.018+02:00", "highlightTitle": ""}